Neurocrine Biosciences CCO Exercises Options and Sells Shares Under Rule 10b5-1 Plan

Executive Summary

On September 9, 2026, Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences Inc ($NBIX), executed an option exercise and partial share sale pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 10, 2026.

Transaction Breakdown

• Option Exercise (Code M): Exercised 3,194 incentive stock options expiring February 6, 2027, with an exercise price of $43.24 per share.
• Open Market Sale (Code S): Sold 2,154 shares of Common Stock at a price of $154.61 per share, generating total gross proceeds of approximately $333,029.94.
• Post-Transaction Holdings: The reporting person continues to directly hold 64,408 shares of Common Stock.

Key Context & Trading Significance

• Significance: Low.
• Pre-Arranged Plan: The transaction was conducted under a Rule 10b5-1 plan established on June 10, 2026.
• Net Impact: Benevich retained approximately 1,040 net shares from the 3,194 option exercise, increasing his baseline direct share count before adjustments (post-transaction balance includes 178 shares acquired via the Employee Stock Purchase Plan).